Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Type
Private
HQ
Utrecht, NL
Founded
2003
Employees
50 (est)+7%
Merus was founded in 2003 and is headquartered in Utrecht, NL

Merus Locations

Utrecht, NL

Merus Metrics

Merus Summary

Founding Date

2003

Total Funding

$149 M

Latest funding size

$79.1 M

Time since last funding

over 1 year

Investors

Merus's latest funding round of $79.1 M was in April 2015. In total, Merus has raised $149 M.
30% of current employees of Merus are female and 70% are male.

Merus News

Merus Company Life